SomaLogic Licenses GNS Healthcare's REFS™ technology for analysis of its SOMAscan®-derived proteomic data

Combining the world-leading proteomic and artificial intelligence/machine learning technologies to produce novel, actionable health insights across many diseases, conditions and markets

News provided by

SomaLogic

Jul 17, 2018, 10:00 ET

BOULDER, Colo., July 17, 2018 /PRNewswire/ -- SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare's proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic's proprietary SOMAscan^®-derived protein data sets. The goal of this agreement is to leverage REFS to rapidly accelerate the translation of SomaLogic's massive protein data into meaningful and actionable information for individual and population health management.

Living organisms function through complicated interconnected biological networks that respond dynamically to factors such as diet, environment, medication, infection and disease. SomaLogic's SOMAscan platform taps into these networks by repeatedly measuring the changing levels of thousands of proteins circulating through the body over time. These large data sets require increasingly powerful machine learning-based tools like GNS Healthcare's unique REFS platform, which builds computational models of the biological networks from the raw data to reveal new understandings of disease and even potential interventions.

"Our ability to measure 5,000 proteins in each of hundreds of thousands of samples requires that we be able to analyze all those data in a way that will ultimately result in making a difference for individuals and their health providers," said Alister Reynolds, CEO of SomaLogic. "We believe that GNS Healthcare's powerful REFS technology has the potential to become a critical tool for extracting those meaningful health insights."

"Our REFS platform has proven itself repeatedly with genomic, transcriptomic, metabolite, clinical, labs, EMR, claims, and other data types, and we are excited to see how well it performs on real-time biological measurements like proteins," said Colin Hill, CEO and co-founder of GNS Healthcare. "SOMAscan-derived protein data are perfectly suited to the REFS workflow, and we look forward to our platform fully proving its value again in this setting."

Further specifics about the agreement were not disclosed.

About GNS Healthcare

GNS Healthcare solves healthcare's matching problem for leading health plans, biopharma companies, and health systems. We transform massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals, improving health outcomes and saving billions of dollars. Our causal learning and simulation platform, REFS, accelerates the discovery of what works for whom and why. Learn more at www.gnshealthcare.com.

About SomaLogic

SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives. These essential insights, which are provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual's proteins over time. For more information, visit www.somalogic.com.

SOURCE SomaLogic